In contrast, TWEAK-induced DEGs in HER2 and ER-positive cell lines displayed a low concordance with the transcriptomic profiles of their respective tumour samples (Supplementary Fig. 6c, d), suggesting the oncogenic activity of the TWEAK/Fn14 pathway may be subtype specific. The gene discussed is ESR1; the disease is neoplasm.